Want to see CTNM full AI Analyst Report?

Contineum Therapeutics, Inc. Class A (CTNM) Price & Analysis

221 Followers

CTNM Stock Chart & Stats

$14.06

$0.22(1.56%)

At close: Jul 27 4:00 PM EDT

$14.06

$0.22(1.56%)

Day’s Range― - ―

52-Week Range$5.07 - $16.91

Previous CloseN/A

Volume15.74K

Average Volume (3M)170.88K

Market Cap

$579.11M

Enterprise Value$384.12

Total Cash (Recent Filing)$236.55M

Total Debt (Recent Filing)$6.57M

Price to Earnings (P/E)―

Beta0.55

Next Earnings

Nov 11, 2026

EPS Estimate

-0.45

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.73

Shares Outstanding32,723,877

10 Day Avg. Volume105,448

30 Day Avg. Volume170,880

Financial Highlights & Ratios

PEG Ratio-0.16

Price to Book (P/B)1.21

Price to Sales (P/S)0.00

P/FCF Ratio-5.70

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$23.40

Price Target Upside66.43% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-1.65

Revenue Forecast (FY)$8.26M

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthContineum’s low leverage and sizable equity base provide durable financial flexibility to fund multi-year R&D programs. A strong balance sheet supports negotiating power with partners, preserves optionality for milestone-driven investments, and lowers near-term solvency risk while clinical readouts progress.

Cash Runway / LiquidityHaving ~$236.6M and an asserted runway through mid-2029 materially reduces near-term financing pressure, allowing Contineum to advance PIPE-791 Phase 2 and related activities. This liquidity window supports execution of trials and partner discussions without immediate dilution risks over the next 2–3 years.

Promising Clinical Data (PIPE-791)Positive Phase 1b safety and exploratory efficacy for PIPE-791 increases the program’s probability of technical success and bolsters its positioning as a lead asset. Durable clinical validation strengthens strategic options: internal development, combination use in IPF, or partnerships, underpinning long-term value potential.

Bears Say

No Recurring Revenue / Persistent LossesContineum remains a pre-revenue, development-stage biotech with sizable operating losses. Persistent lack of product revenue means long-term sustainability depends on successful clinical outcomes or deal-generated milestone revenue; absent those, financing and dilution risk persist as structural threats.

Rising Cash BurnOperating and free cash flow trends show accelerating cash burn year-over-year, increasing the company’s reliance on its cash buffer or fresh financing to maintain development momentum. Even with current runway, prolonged higher burn increases execution risk if trials extend or require expansion.

Concentrated Pipeline & Partner DependenceFocusing resources on PIPE-791 while deferring CTX-343 and depending on a Janssen partnership for PIPE-307 concentrates development risk into fewer catalysts. This reduces diversification of clinical assets and increases exposure to single-program setbacks or third-party partner timelines and decisions.

Contineum Therapeutics, Inc. Class A News

Contineum initiated with an Outperform at LifeSci Capital

LifeSci Capital initiated coverage of Contineum (CTNM) with an Outperform rating and $24 price target Published first on...

2d ago

CTNM

Contineum reports Q2 EPS (40c), consensus (45c)

Cash, cash equivalents and marketable securities were $236.6 million as of June 30, 2026. Contineum (CTNM) believes its...

3d ago

CTNM

Buy Rating Reaffirmed on Contineum Therapeutics with Unchanged $26 Price Target, Backed by Advancing IPF and MDD Pipelines

JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on CTNM stock, giving a Buy rating today. Debanjana...

2d ago

CTNM

Analyst Initiates Buy on Contineum, Citing PIPE-791’s Differentiated IPF Profile and Favorable Risk-Reward Ahead of Key 2026 Readthrough

Contineum Therapeutics, Inc. Class A, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst...

3d ago

CTNM

Contineum Therapeutics Updates Strategy, Highlights PIPE-791 Leadership

Contineum Therapeutics, Inc. Class A ( ($CTNM) ) has issued an announcement. On July 13, 2026, Contineum Therapeutics...

20d ago

CTNM

Contineum publishes manuscript on PIPE-791 in Journal of Medicinal Chemistry

Contineum (CTNM) Therapeutics announced the publication of a manuscript describing the discovery and characterization of PIPE-791 in the...

1M ago

CTNM

Contineum Stockholders Hold 2026 Virtual Annual Meeting

Contineum Therapeutics, Inc. Class A ( ($CTNM) ) has provided an update. On June 26, 2026, Contineum Therapeutics,...

1M ago

CTNM

Contineum price target raised to $16 from $14 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Contineum (CTNM) to $16 from $14 and keeps an Equal...

3M ago

CTNM

Contineum Therapeutics Reports Positive Phase 1b Chronic Pain Data

Contineum Therapeutics, Inc. Class A ( ($CTNM) ) has issued an update. On April 30, 2026, Contineum Therapeutics...

3M ago

CTNM

Contineum reports positive topline data from exploratory PIPE-791 Phase 1b

Contineum (CTNM) Therapeutics reported positive topline data from its exploratory Phase 1b trial of PIPE-791, a potentially best-in-class...

3M ago

CTNM

Contineum price target raised to $20 from $14 at Baird

Baird analyst Charles Moore raised the firm’s price target on Contineum (CTNM) to $20 from $14 and keeps...

5M ago

CTNM

Contineum Therapeutics Expands ATM Facility, Highlights Pipeline Progress

The latest announcement is out from Contineum Therapeutics, Inc. Class A ( ($CTNM) ). Contineum Therapeutics amended its...

5M ago

CTNM

Contineum reports Q4 EPS (49c), consensus (39c)

Cash, cash equivalents and marketable securities were $262.9 million as of December 31, 2025. Contineum (CTNM) believes its...

5M ago

CTNM

Is CTNM a Buy, Before Earnings?

Contineum Therapeutics, Inc. Class A (CTNM) is scheduled to report 4th quarter earnings on 03/05/2026. Regarding Q4 estimates,...

5M ago

CTNM

CTNM FAQ

What was Contineum Therapeutics, Inc. Class A’s price range in the past 12 months?

Contineum Therapeutics, Inc. Class A lowest stock price was $5.07 and its highest was $16.91 in the past 12 months.

What is Contineum Therapeutics, Inc. Class A’s market cap?

Contineum Therapeutics, Inc. Class A’s market cap is $579.11M.

When is Contineum Therapeutics, Inc. Class A’s upcoming earnings report date?

Contineum Therapeutics, Inc. Class A’s upcoming earnings report date is Nov 11, 2026 which is in 101 days.

How were Contineum Therapeutics, Inc. Class A’s earnings last quarter?

Contineum Therapeutics, Inc. Class A released its earnings results on Jul 30, 2026. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.449 by $0.049.

Is Contineum Therapeutics, Inc. Class A overvalued?

According to Wall Street analysts Contineum Therapeutics, Inc. Class A’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Contineum Therapeutics, Inc. Class A pay dividends?

Contineum Therapeutics, Inc. Class A does not currently pay dividends.

What is Contineum Therapeutics, Inc. Class A’s EPS estimate?

Contineum Therapeutics, Inc. Class A’s EPS estimate is -0.45.

How many shares outstanding does Contineum Therapeutics, Inc. Class A have?

Contineum Therapeutics, Inc. Class A has 32,723,877 shares outstanding.

What happened to Contineum Therapeutics, Inc. Class A’s price movement after its last earnings report?

Contineum Therapeutics, Inc. Class A reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.449. Following the earnings report the stock price went down -1.651%.

Which hedge fund is a major shareholder of Contineum Therapeutics, Inc. Class A?

Currently, no hedge funds are holding shares in CTNM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Contineum Therapeutics, Inc. Class A Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

36.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Contineum Therapeutics, Inc. Class A

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

Contineum Therapeutics, Inc. Class A (CTNM) Earnings & Revenues

Historic Earnings Reports

CTNM Stock 12 Month Forecast

Average Price Target

$23.40

▲(66.43% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","29":"$29","8.75":"$8.75","15.5":"$15.5","22.25":"$22.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8.75,15.5,22.25,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.24,16.22153846153846,17.203076923076924,18.184615384615384,19.166153846153847,20.147692307692306,21.12923076923077,22.11076923076923,23.092307692307692,24.073846153846155,25.055384615384614,26.036923076923074,27.018461538461537,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.24,15.867692307692307,16.495384615384616,17.123076923076923,17.75076923076923,18.378461538461536,19.006153846153847,19.633846153846154,20.26153846153846,20.889230769230767,21.516923076923078,22.144615384615385,22.77230769230769,{"y":23.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.24,15.298461538461538,15.356923076923078,15.415384615384616,15.473846153846154,15.532307692307693,15.590769230769231,15.649230769230769,15.707692307692307,15.766153846153847,15.824615384615385,15.883076923076922,15.941538461538462,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.17,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.01,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.43,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.38,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.34,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.45,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.09,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.24,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >